Hot melt extrusion (HME) is the process of using heat and presser for melting polymer and continuously forcing the material through an orifice. HME process has been developed for producing polymer products with uniform shape and density and has been used in industrial application since the 1930s. Recently, HME technology has been brought in use in pharmaceutical application where it is dominantly used for manufacturing APIs with polymers to augment bioavailability or prepare precursors for thermoplastic drug eluting devices.
Control valves are regarded among the most integral parts of various manufacturing and process industries. Features such as effective flow rate control and consequential control of process quantities such as temperature, pressure and fluid level make them highly essential for carrying industrial processes seamlessly.
Xanthan gum is a complex exopolysaccharide, it is a polymer composed of sugar residues, secreted by a microorganism into the surrounding environment. Xanthan gum is widely used as a thickening and stabilizing agent in a wide variety of food & beverages and industrial products. Some of the common uses of xanthan gum finds in Cosmetics, Baked goods and pastry fillings, Ice cream and sherbet, Industrial uses, Jams, jellies and sauces, Lotions, Medicines, Pudding, Salad dressings, Toothpastes, Yogurt, etc. In oilfield applications xanthan gum provides excellent rheological control for water-based drilling, completion and work-over fluids in a wide range of brines.
Nuclear medicine/ radiopharmaceuticals are agents used to diagnose certain medical problems or treat certain diseases condition. Increasing awareness of radiopharmaceuticals, growing number of pharmaceutical companies and rising research institutes are major factors that assisting the growth of nuclear medicine/ radiopharmaceuticals market globally.
The beta glucan is considered as an important functional ingredient with numerous health benefits. The industries are adopting beta-glucan to fortify foodstuff with high dietary fibres as consumer interests in the nutraceutical products is on escalation. Furthermore beta-glucan actively impacts the metabolic parameters and help curing the chronic diseases.
The biological safety testing market is set to reach US$ 8,935.4 Mn by 2026 from US$ 3,120.8 Mn in 2017 growing at an impressive pace with a compounded annual growth rate (CAGR) of 12.5% during the forecast period from 2018 to 2026. The primary features responsible for the biological safety testing market are rising prevalence of chronic diseases and rapid growth in the clinical laboratories worldwide.
Rabies is a fatal neurological disease, usually spread to humans through the bite of a rabid animal, and it is a persistent global problem. Factors such growing treatment awareness and rising initiatives of government organizations in prevention of rabies are primarily driving the growth of human rabies treatment market globally.
Acute renal failure is a rapid onset of renal function impairment which is potentially reversible depending on the cause and the extent of being untreated. Acute renal failure is a common condition experienced during critical illness and ICU admission.
Industrial gases are gaseous materials that are manufactured for use in the industry. The principal industrial gases available are oxygen, nitrogen, helium, acetylene, argon, hydrogen, carbon dioxide and others (krypton, xenon, methane, carbon monoxide, etc.).
Gout is a complex form of inflammatory arthritis characterized by recurrent attacks of a severe pain and swollen joints. Gout therapeutics market is rapidly growing due to factors such as growing incidence of gout, significant unmet needs, growing treatment awareness, and promising pipeline molecules. The incidence of gout varies widely around the globe, with developed countries generally having higher prevalence than developing countries due to genetic, dietary and environmental factors.
The drugs by therapeutic area include therapy for oncology, cardiovascular, central nervous system, infectious diseases, respiratory, and others. The therapeutic area represents the specific area of medicine where the drug is intended to be used, based on its mechanism of action and intended clinical use. One of the primary drivers of the drugs by therapeutic area market is the increasing prevalence of diseases worldwide. Chronic diseases such as cancer, cardiovascular diseases, and neurological disorders are a significant burden on healthcare systems globally. There is an urgent need for new and effective therapies to treat these diseases, which has led to the growth of the drugs in the therapeutic area market.
The revenues generated by the drugs in the therapeutic area market have been consistently high over the years. The global pharmaceutical market is expected to reach USD 1.5 trillion by 2023, with oncology being the leading therapeutic area. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the drugs by therapeutic area market is the increasing use of precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of drugs in the therapeutic area market.
Another trend in the drugs by therapeutic area market is the increasing focus on biologics. Biologics are drugs that are produced from living cells and are used to treat a wide range of diseases, including cancer and autoimmune disorders. Biologics are more complex than traditional small-molecule drugs, and their development requires specialized manufacturing processes and clinical trial design. The increasing demand for biologics has contributed to the growth of the drugs by therapeutic area market. The increasing focus on rare diseases is also driving the growth of the drugs by therapeutic area market. Rare diseases are defined as diseases that affect fewer than 200,000 people in the United States. Although each rare disease affects a small number of people, there are over 7,000 rare diseases, which together affect millions of people worldwide. There is an urgent need for new therapies to treat rare diseases, which has led to the growth of drugs in the therapeutic area market.
The increasing use of combination therapies is driving the growth of the drugs by therapeutic area market. Combination therapies involve the use of two or more drugs to treat a disease. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the drugs by therapeutic area market. The increasing prevalence of diseases worldwide, advancements in technology, and the emerging trends in precision medicine, biologics, rare diseases, and combination therapies are expected to drive the growth of the drugs by therapeutic area market.
